Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chabiotech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩628.02B | -73.8x | -3.89 | ₩11,270 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GC Cell | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩360.65B | -109.3x | -1.55 | ₩23,500 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Labgenomics | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩229.4B | -8.7x | 0.02 | ₩2,970 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DT CRO | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩77.4B | 34.3x | ₩6,050 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Dreamcis | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩71.16B | 15.6x | 0.07 | ₩2,975 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biotoxtech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩52.9B | -11.3x | -0.76 | ₩3,300 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
U2Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩34.6B | 67.8x | ₩3,090 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
SLS Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩27.18B | 28.2x | ₩1,970 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |